Questions About Cancer? 1-800-4-CANCER

Primary CNS Lymphoma Treatment (PDQ®)

Health Professional Version
Last Modified: 01/03/2014

Changes to This Summary (01/03/2014)

The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.

Treatment Option Overview

Added text to state that patients with recurrent or refractory central nervous system lymphoma after methotrexate-based chemotherapy are candidates for salvage chemotherapy (cited Khimani et al. as reference 26).

Added text to state that in a randomized, nonblinded, multicenter trial, 79 patients were randomly assigned to high-dose methotrexate versus high-dose methotrexate plus cytarabine; however, while 3-year progression-free survival was better for the 2-drug regimen, there was no difference in 3-year overall survival (cited Ferreri et al. as reference 41 and level of evidence 1iiDiii).

This summary is written and maintained by the PDQ Adult Treatment Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ NCI's Comprehensive Cancer Database pages.